Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

NCT06188676 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

100

Enrollment

NETWORK

Sponsor class

Conditions

Primary Mediastinal Lymphoma

Interventions

DRUG: Cyclophosphamide
DRUG: Doxorubicin Hydrochloride
DRUG: Etoposide Phosphate
DRUG: Prednisolone
DRUG: Rituximab
DRUG: Vincristine Sulfate
DRUG: Filgrastim
DRUG: Pegfilgrastim
DRUG: Nivolumab 40 mg in 4 ml Injection

Sponsor

National Research Center for Hematology, Russia